Publications by authors named "You-yan Guan"
Objective: Immunotherapy-tyrosine kinase inhibitor (IO-TKI) therapy has revolutionized the treatment landscape for metastatic clear cell renal cell carcinoma (mccRCC); however, the absence of effective biomarkers poses a challenge in predicting the efficacy of these regimens. This study aims to explore the predictive and prognostic value of serum immunoglobulin A (IgA) in mccRCC patients undergoing IO-TKI therapy.
Methods: Ninety-six mccRCC patients treated with IO-TKI therapy from 2019 to 2023 were enrolled and serum IgA levels were assessed at the pretreatment baseline and after 3 months of treatment.
Article Synopsis
- The study looked at immune cells in muscle-invasive bladder cancer before and after treatment with chemotherapy to see how they change and what that means for patients.
- Researchers tested different types of immune cells in 54 patients' tissues and found that certain cells called TAMs decreased after treatment.
- They discovered that higher levels of these TAMs might mean a patient could have a worse chance of staying cancer-free after treatment, but they couldn't use other immune cells to predict how well patients would respond to chemotherapy.
Objective: To assess serum levels of endogenous endostatin in patients with clear cell renal cell carcinoma (CCRCC) and to determine the relationship of these levels to tumor stage, grade.
Methods: From March 2004 to October 2008, preoperative serum were obtained from 138 consecutive patients with CCRCC (73 patients in T1, 39 patients in T2, 20 patients in T3, and 6 patients in T4) and 40 healthy controls. Serum levels of endostatin were measured by sandwich-ELISA.
Objective: To evaluate the prognostic factors of ureter transitional cell carcinoma (TCC).
Methods: Between January 2001 and December 2005 133 TCC patients were treated. And the data was retrospectively analyzed.